Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement.

Autor: Lopetegui-Lia N; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Dima D; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Buchberger DS; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Yalamanchali A; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Osantowski B; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Ondeck M; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Lorenz RR; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Prendes B; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Ku J; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Lamarre E; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Scharpf J; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Silver NL; Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Schwartzman L; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Geiger JL; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Woody NM; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Campbell SR; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Koyfman SA; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Yilmaz E; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2023 Aug; Vol. 45 (8), pp. 2149-2154. Date of Electronic Publication: 2023 Jun 05.
DOI: 10.1002/hed.27419
Abstrakt: Background: Metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) can be treated with immunotherapy (IO). Cranial nerve involvement (CNI) is uncommon in cSCC and is a poor prognostic factor. Our aim is to describe how patients with CNI respond to IO monotherapy and/or as an adjunct to RT.
Methods: Under an IRB approved protocol, patients with histologically proven cSCC of the head and neck with CNI treated with IO were retrospectively reviewed.
Results: Twelve patients were included and received cemiplimab or pembrolizumab. Eight patients had CNI at diagnosis, and 4 at time of recurrence after non-IO therapy. Best responses were complete response (1), partial response (7), stable disease (1), progressive disease (2), and pending response (1). Nine patients are alive, 6 of which remain on IO.
Conclusions: In this cohort, IO showed clinical response in 83% of patients, indicating IO can be an effective monotherapy, reserving RT for instances of local failure after IO.
(© 2023 The Authors. Head & Neck published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: